Nevimune
Nevimune is an antiretroviral medication containing Nevirapine, which is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). It works by blocking HIV reverse transcriptase, an enzyme required for viral replication, thereby lowering the viral load in the body.
Dosage by Body Weight
Requires a 14-day lead-in period of 200 mg once daily to reduce the risk of severe skin rash, followed by a maintenance dose of 200 mg twice daily. Must always be used in combination with other antiretroviral drugs. Pediatric dosing is weight-based.
- Body Weight
- Below 5 kg
- Dose
- 4 ml (40 mg) or calculated at 4 mg/kg
- Frequency
- Once daily for 14 days, then twice daily
- Tracking Notes
- Use with extreme caution. Close monitoring for clinical adverse signs is necessary.
- Body Weight
- 5-7 kg
- Dose
- 50 mg (5 ml suspension)
- Frequency
- Twice daily (after a 14-day once-daily lead-in)
- Tracking Notes
- Lead-in phase of 50 mg once daily is critical to prevent hypersensitivity.
- Body Weight
- 8-10 kg
- Dose
- 80 mg to 100 mg (8 ml to 10 ml suspension)
- Frequency
- Twice daily
- Tracking Notes
- Ensure patient is adherent to the full antiretroviral regimen.
- Body Weight
- 11-15 kg
- Dose
- 120 mg to 150 mg
- Frequency
- Twice daily
- Tracking Notes
- Tablet formulations (dispersible) can be introduced if the child can swallow or tolerate them.
- Body Weight
- 16-20 kg
- Dose
- 150 mg to 200 mg
- Frequency
- Twice daily
- Tracking Notes
- Do not exceed the maximum adult maintenance dose of 200 mg twice daily.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 4 ml (40 mg) or calculated at 4 mg/kg | Once daily for 14 days, then twice daily | Use with extreme caution. Close monitoring for clinical adverse signs is necessary. |
| 5-7 kg | 50 mg (5 ml suspension) | Twice daily (after a 14-day once-daily lead-in) | Lead-in phase of 50 mg once daily is critical to prevent hypersensitivity. |
| 8-10 kg | 80 mg to 100 mg (8 ml to 10 ml suspension) | Twice daily | Ensure patient is adherent to the full antiretroviral regimen. |
| 11-15 kg | 120 mg to 150 mg | Twice daily | Tablet formulations (dispersible) can be introduced if the child can swallow or tolerate them. |
| 16-20 kg | 150 mg to 200 mg | Twice daily | Do not exceed the maximum adult maintenance dose of 200 mg twice daily. |
Formulation
Purpose
Used in combination with other antiretroviral agents for the treatment of HIV-1 infection and for the prevention of maternal-fetal transmission of HIV-1.
Generic Name
NevirapineBranded Drug Names
Nevimune is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.